Nomura Holdings’s BioMarin Pharmaceuticals BMRN Stock Holding History

Nomura Holdings’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-30,000	Closed	-$1.69M	–	1814
2026 Q1	$1.69M	Hold	30,000	–	–	﹤0.01%	979
2025 Q4	$1.78M	Hold	30,000	–	–	﹤0.01%	1139
2025 Q3	$1.62M	Sell	30,000 -27,000	-47%	-$1.54M	﹤0.01%	1223
2025 Q2	$3.13M	Buy	+57,000	New	+$3.36M	0.01%	702
2025 Q1	–	Sell	-41,300	Closed	-$2.71M	–	1804
2024 Q4	$2.71M	Buy	41,300 +33,900	+458%	+$2.27M	﹤0.01%	993
2024 Q3	$520K	Sell	7,400 -3,300	-31%	-$276K	﹤0.01%	1244
2024 Q2	$881K	Sell	10,700 -51,100	-83%	-$4.25M	﹤0.01%	1179
2024 Q1	$5.4M	Buy	+61,800	New	+$5.53M	0.01%	623
2019 Q4	–	Sell	-40,000	Closed	-$2.59M	–	1106
2019 Q3	$2.59M	Buy	+40,000	New	+$3.08M	0.01%	600

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Nomura Holdings's BMRN Position: Q2 2026 in Review

Nomura Holdings reduced its BioMarin Pharmaceuticals (BMRN) stake by 33% in Q2 2026, selling an estimated $548K and leaving 20,000 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #1318.

Nomura Holdings first reported a position in BMRN in Q2 2013 and has held it in 43 quarters since. The position peaked at $251M in Q3 2023. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Nomura Holdings held 20,000 shares of BioMarin Pharmaceuticals worth $1.14M as of Q2 2026.
Nomura Holdings sold 10,000 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $548K.
BioMarin Pharmaceuticals made up ﹤0.01% of Nomura Holdings's portfolio in Q2 2026, its #1318 holding.
Nomura Holdings first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 43 quarters since.
Nomura Holdings's BioMarin Pharmaceuticals position peaked at $251M in Q3 2023.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Nomura Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.